



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
February 2, 2021

Therapeutic Class	Drug Name	DURB Recommendation
Anticonvulsants		
	<i>Fintepla (Oral) Solution</i>	NP/PA
Biologic Immunomodulators		
	<i>Enspryng (Subcutaneous) Injection</i> <i>Uplizna (Intravenous) Injection</i>	NP/PA P/PA (for coverage on the PADL)
HIV/AIDS		
	<i>Rukobia (Oral) Tablet</i>	NP/PA
Multiple Sclerosis Agents		
	<i>Zeposia (Oral) Capsule</i>	NP/PA
Sedative Hypnotics		
	<i>Dayvigo (Oral) Tablet</i>	NP/PA
Spinal Muscular Atrophy		
	<i>Evrysdi (Oral) Solution</i> <i>Spinraza (Intrathecal) Solution</i>	P/PA NP/PA (for coverage on the PADL)

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List